Lung adenocarcinoma with EGFR and KIF5B-MET co-mutations: A case report

With the development of genetic testing technology, it has become a mainstream to detect molecular alterations in lung cancer patients to guide clinical targeted therapy. This article reports a 51 year-old male patient diagnosed as lung adenocarcinoma in the molecular pathology diagnostic laboratory of Department of Pathology of the First Medical Center of Chinese PLA General Hospital, with clinical TNM stage T1bN0M0, and double mutation of rare gene fusion of EGFR (L858R) and KIF5B-MET by second-generation sequencing. The patient underwent video-assisted thoracoscopic surgery (VATS), which involved resection of the upper lobe of the right lung and clearance of the mediastinal lymph nodes. After surgery, no targeted therapy or radiotherapy was performed, and the prognosis was good since the follow-up. By analyzing the clinical data, diagnosis and treatment process and disease regression of the patient, the new mutation forms and related therapeutic targets in non-small cell lung cancer (NSCLC) patients are investigated, suggesting that early radical lung cancer treatment is effective, and second-generation sequencing is important for identifying rare mutations and therapeutic targets.